As of 2026-11-04, this source-verified dataset records 8 Taiwan biotech out-licensing agreements announced in 2026; the largest disclosed upfront was Foresee Pharmaceuticals Co., Ltd. (through Foresee Pharmaceuticals USA Inc.) → Primevera Therapeutics, LLC (FP-025; FP-020; third-generation MMP-12 inhibitors; USD 10,000,000).
Data updated：
TLC-KY／台灣微脂體股份有限公司 → Nippon Zoki Pharmaceutical Co., Ltd.
瑩碩生技 → YS Life Science
順藥 → 安美得生醫股份有限公司
台新藥股份有限公司 → Samil Pharmaceuticals Co., Ltd.
台新藥股份有限公司 → Arrotex Pharmaceuticals Pty Ltd.
太景醫藥研發控股股份有限公司 → Boryung Biopharma Co., Ltd.
台新藥股份有限公司 → Samil Pharmaceuticals Co., Ltd.
逸達生物科技股份有限公司 → Primevera Therapeutics, LLC
8 source-verified agreements; announcement year is used if the signing date is undisclosed. This is a tracked subset, not a market census.
As of 2026-11-04, this source-verified dataset records 8 Taiwan biotech out-licensing agreements announced in 2026; the largest disclosed upfront was Foresee Pharmaceuticals Co., Ltd. (through Foresee Pharmaceuticals USA Inc.) → Primevera Therapeutics, LLC (FP-025; FP-020; third-generation MMP-12 inhibitors; USD 10,000,000).
Australia, Japan, South Korea, Taiwan, United States. Licensee domicile differs from licensed territory.
Formosa Pharmaceuticals, Inc.: 3. Agreements are counted once, including multi-asset agreements.
USD: disclosed upfronts USD 10,000,000 from 1 agreements. Undisclosed amounts are excluded. Currencies, upfronts, conditional payments and disclosed total caps are kept separate.
Method: merge the Asian tracker and search_deals; verify primary sources, deduplicate agreements, preserve undisclosed values and original currencies.
